May 3 2013
Medscape: High Price Of Cancer Drugs Is Harming Patients
The extremely high prices of recent cancer drugs "may be causing harm to patients," a large group of international leukemia experts warns. In a forum article published online April 25 in Blood, the group of 120 experts from around the world discuss the high cost of leukemia drugs, but emphasize that their concerns extend to many other types of cancer drugs. The high price of drugs has resulted in nonadherence to treatment, they note. In the United States, about 10% of patients fail to take prescribed drugs, largely because of cost. "This is reducing their chances of survival," they point out (Chustecka, 5/1).
|
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths